NCT02269488View on ClinicalTrials.gov

A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Healthy Japanese Children Age 2 Years Through 6 Years
Interventions
DRUG

MEDI3250

MEDI3250

Trial Locations (3)

Unknown

Research Site, Kameyama-shi

Research Site, Suzuka-shi

Research Site, Tsu

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY